1. Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
- Author
-
Huibi Cao, Juntao Mai, Zhichang Zhou, Zhijie Li, Rongqi Duan, Jacqueline Watt, Ziyan Chen, Ranmal Avinash Bandara, Ming Li, Sang Kyun Ahn, Betty Poon, Natasha Christie-Holmes, Scott D. Gray-Owen, Arinjay Banerjee, Karen Mossman, Rob Kozak, Samira Mubareka, James M. Rini, Jim Hu, and Jun Liu
- Subjects
COVID-19 ,HD-Ad ,Nasal delivery ,SARS-CoV2 ,Vaccine ,Biotechnology ,TP248.13-248.65 ,Biology (General) ,QH301-705.5 ,Biochemistry ,QD415-436 - Abstract
Abstract Background The ongoing COVID-19 pandemic has resulted in 185 million recorded cases and over 4 million deaths worldwide. Several COVID-19 vaccines have been approved for emergency use in humans and are being used in many countries. However, all the approved vaccines are administered by intramuscular injection and this may not prevent upper airway infection or viral transmission. Results Here, we describe a novel, intranasally delivered COVID-19 vaccine based on a helper-dependent adenoviral (HD-Ad) vector. The vaccine (HD-Ad_RBD) produces a soluble secreted form of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and we show it induced robust mucosal and systemic immunity. Moreover, intranasal immunization of K18-hACE2 mice with HD-Ad_RBD using a prime-boost regimen, resulted in complete protection of the upper respiratory tract against SARS-CoV-2 infection. Conclusion Our approaches provide a powerful platform for constructing highly effective vaccines targeting SARS-CoV-2 and its emerging variants.
- Published
- 2021
- Full Text
- View/download PDF